Full history for every metric is available with a Kvantra account
Toleranzia AB (TOL.ST)
Key financial summary
Financials in SEK| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | SEK m | 7 | 13 | 28 | 35 | 51 | 30 | 24 |
| Operating profit | SEK m | -10 | -13 | |||||
| Net profit | SEK m | -10 | -5 | -6 | -8 | -7 | -9 | -13 |
| EPS reported | SEK | -0.04 | -0.05 | |||||
| Operating cashflow per share | SEK | -0.05 | -0.03 | |||||
| Capex per share | SEK | 0.14 | 0.02 | |||||
| FCF per share | SEK | -0.19 | -0.03 | |||||
| Free cash flow | SEK m | -41 | -21 | |||||
| Net debt | SEK m | -14 | -2 | |||||
| Book value equity | SEK m | 180 | 174 | |||||
| Book value per share | SEK | 0.85 | 0.64 | |||||
| Number of shares | m | 211.4 | 270.96 | |||||
| DPS (TTM paid) | SEK | 0.00 | 0.00 |
Financial summary
Financials in SEK| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.70 | 0.74 | |||||
| P/S LTM | x | 4.18 | 5.43 | |||||
| P/FCF LTM | x | -3.10 | -6.16 | |||||
| EV/EBITDA LTM | x | -9.89 | -10.00 | |||||
| EV/Sales LTM | x | 3.72 | 5.33 | |||||
| Earnings Yield LTM | % | -7.51% | -4.80% | |||||
| FCF Yield | % | -32.27% | -16.24% | |||||
| Quality | ||||||||
| ROE | % | -5.24% | -3.54% | |||||
| ROIC | % | -5.69% | -3.43% | |||||
| Operating margin | % | -34.13% | -114.27% | |||||
| Gross margin | % | -13.80% | 51.42% | |||||
| FCF/Sales | % | -134.94% | -133.68% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -41.03% | -29.49% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 1.22 | 0.39 | |||||
| EBIT/Net interest | x | -28.39 | -42.85 | |||||
| Net debt/market cap | % | -10.97% | -1.83% | |||||
| Net debt/Equity | x | -0.08 | -0.01 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Toleranzia AB is a Swedish biotechnology firm focused on creating and bringing to market pharmaceutical solutions for rare autoimmune conditions. Its lead experimental medication, TOL2, targets myasthenia gravis, a debilitating autoimmune disorder affecting nerves and muscles. Additionally, the firm plans to advance TOL3, another investigational compound, to address ANCA vasculitis, which is an autoimmune ailment of the blood vessels. Furthermore, Toleranzia is pioneering its tolerogens technology, an innovative therapeutic approach designed to induce disease-specific immune tolerance across a range of autoimmune disorders. Established in 2011, this enterprise operates out of its headquarters located in Gothenburg, Sweden.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Toleranzia AB (TOL.ST)
Toleranzia AB is a Swedish biotechnology firm focused on creating and bringing to market pharmaceutical solutions for rare autoimmune conditions. Its lead experimental medication, TOL2, targets myasthenia gravis, a debilitating autoimmune disorder affecting nerves and muscles. Additionally, the firm plans to advance TOL3, another investigational compound, to address ANCA vasculitis, which is an autoimmune ailment of the blood vessels. Furthermore, Toleranzia is pioneering its tolerogens technology, an innovative therapeutic approach designed to induce disease-specific immune tolerance across a range of autoimmune disorders. Established in 2011, this enterprise operates out of its headquarters located in Gothenburg, Sweden.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free